Device Trial Radar · NCT03853356
Evidence For Fusion In Spine With Orthoss®
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Jan 18, 2019
Primary completion
Jul 17, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Geistlich Pharma AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 25, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the performance and safety of the Orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).
Conditions
- Lumbar Spondylolisthesis Involving L4-L5
- Lumbar Spondylolisthesis Involving L5-S1
- Lumbar Spinal Stenosis
- Lumbar Disc Degeneration
Interventions
OrthossDevice
Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fusion rateTime frame: 6 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Augsburg - Neurochirurgische Klinik und Poliklinik
Augsburg, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Klinikum Magdeburg gGmbH
Magdeburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.